NCT05974852

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 732 (actual)
• Sponsor: State University of New York at Buffalo · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: —

Summary

The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.

Detailed description

To study the effect of ocrelizumab on choroid plexus changes in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study

Conditions

• Primary Progressive Multiple Sclerosis

Interventions

Type	Name	Description
OTHER	Ocrelizumab	Non-interventional

Timeline

• Start date: 2023-10-01
• Primary completion: 2023-12-30
• Completion: 2023-12-30
• First posted: 2023-08-03
• Last updated: 2026-03-09

Locations

1 site across 1 country: United States